Shawah Robert G. 4

What Happened
Robert G. Shawah, Chief Financial Officer of Acurx Pharmaceuticals, was granted options to purchase 25,900 shares of the company's common stock on April 20, 2026. The Form 4 reports the award as a derivative acquisition at $0.00 (grant of option rights), not an outright purchase or sale.

Key Details

• Transaction date: April 20, 2026; Form 4 filed April 22, 2026 (within normal reporting window).
• Transaction type: Award — stock options (derivative), 25,900 options granted; reported price $0.00.
• Vesting: Options vest in 36 equal monthly installments starting on the grant date (per footnote F1).
• Shares owned after transaction: not disclosed in this filing.
• Footnote: F1 confirms grant date and monthly 36-month vesting schedule.
• Timeliness: Filing appears timely (filed two days after the grant).

Context
This was an option grant as compensation, not an exercise or sale. Option grants are routine for executives and do not represent an immediate personal purchase or liquidation. Retail investors should view such grants as part of executive pay arrangements rather than a direct endorsement or rejection of the stock.